DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
DBV Technologies (Nasdaq: DBVT) announced that CEO Daniel Tassé will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference.
Rhea-AI Summary
DBV Technologies (Nasdaq: DBVT) announced that CEO Daniel Tassé will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference.
The session is scheduled for June 9, 2026, at 9:20 AM ET in Miami, with a live webcast and 90-day replay on the company’s investor website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – DBVT
In the Jun 8 session, DBVT declined 3.56%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference edition
- 47th
- Goldman Sachs Annual Global Healthcare Conference
- Conference date
- June 9, 2026
- Scheduled fireside chat at Goldman Sachs conference
- Start time
- 9:20 AM ET
- Scheduled time for DBV CEO fireside chat
- Replay duration
- 90 days
- Archived webcast replay availability after event
Historical Context
-
First participant screened in THRIVE Phase 2 VIASKIN Peanut Patch study.
-
Announcement and logistics for June 3, 2026 Combined General Meeting.
-
CEO fireside chat at H.C. Wainwright BioConnect investor conference.
-
Reported Q1 2026 results, cash level and net loss for the quarter.
-
Updated total shares and voting rights as of March 31, 2026.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Châtillon, France, June 5, 2026
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 9:20 AM ET, in Miami, FL.
A live webcast of the fireside chat can be accessed here, and will also be available on the Events section of the Company’s Investors website: https://dbv-technologies.com/investor-overview/events/, with an archived replay accessible for 90 days following the event.
About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
VIASKIN is a registered trademark of DBV Technologies.
Investor Relations Contact
Jonathan Neely
DBV Technologies
jonathan.neely@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.